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Introduction
Thromboembolic disease remains a major cause of
morbidity and mortality in many countries. Since
1993, factor V Leiden and PT20210 A allele have been
found to be the major causes of thromboembolic
disease in the West. However, Chinese people are less
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B vitamins and other factors on plasma homocysteine (Hcy) levels and risk of thromboembolic disease in Chinese.
Methods: One hundred and six subjects were enrolled into the study. They were categorized into 4 groups: healthy
individuals (n = 42); those with diabetes mellitus (n = 20); those with deep vein thrombosis (DVT) (n = 11); and
those with coronary artery disease (CAD) (n = 33). Plasma levels of folic acid, vitamins B6 and B12, Hcy, and fasting
blood sugar were measured; total cholesterol, triglycerides, complete blood count, and 677 CAT mutation in MTHFR
were determined.
Results: Plasma Hcy was lowest in the healthy subjects, higher in diabetics, followed by patients with DVT, and highest
in patients with CAD (p < 0.001, ANOVA). MTHFR C677T polymorphism was the common factor affecting plasma logHcy
levels in all 4 groups of subjects. Triglycerides affected plasma logHcy in the CAD patients. For the 4 groups as a
whole, MTHFR polymorphism, triglycerides, and vitamin B12 were the most significant factors influencing plasma Hcy.
Conclusion: We suggest that high plasma Hcy is an important risk factor for CAD. Other factors including MTHFR
polymorphism, vitamin B12, triglycerides, total cholesterol, and gender might affect Hcy levels in different diseases
and conditions. [J Chin Med Assoc 2005;68(12):560–565]
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prone to thromboembolic disease.1–3 While our recent
studies in Chinese populations found neither factor V
Leiden nor PT20210 A allele,4–6 we did find that the
Chinese carried the same methylenetetrahydrofolate
reductase (MTHFR) gene polymorphism as described
in Western studies,6 with the CAT substitution at
nucleotide 677 being another possible cause of
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thrombosis. Whether or not this polymorphism can
affect homocysteine (Hcy) levels in Chinese patients
deserves our investigation. The present study was,
thus, conducted to determine the influence of MTHFR
gene polymorphism, B vitamins and other possible
factors on plasma Hcy levels and risk of thromboembolic
disease in Chinese.
Methods
A total of 106 subjects were enrolled into the study
and divided into 4 groups. Group A comprised healthy
subjects without a history of diabetes mellitus (DM),
thromboembolic disease, or of taking any medication
in the previous 2 weeks. Group B included patients
with type 2 DM with normal renal function. Group C
had patients with deep vein thrombosis (DVT) as
shown on sonogram. Group D included patients with
coronary artery disease (CAD) as shown on angiogram,
with at least 1 major vessel having more than 75%
stenosis.
After signed informed consent was obtained from
each subject, blood samples were taken (between 9
and 10 a.m.) after a 12-hour fast, and not at the acute
stage for patients with DVT, in order to test for
MTHFR gene mutations, and to measure plasma Hcy
levels, complete blood count, total cholesterol,
triglycerides, fasting blood sugar (FBS), and vitamin
B6, vitamin B12 and folate levels.
DNA analysis for the MTHFR 677CAT
polymorphism was performed using the methods
described by Frosst et al.7 DNA was extracted from the
buffy coat of the collected peripheral blood as previously
described7 and approximately 0.5 μg was used for
amplification by the polymerase chain reaction (PCR).
The DNA samples were stored at 4°C for not more
than 12 months before they were analyzed.
To detect the 677CAT transition in the MTHFR
gene, PCR was performed with 5 lM of forward and
reverse primers7 in 80 μM dNTPs, 10 mM Tris-HCl,
pH 8.8 at 25°C, 1.5 mM MgCl2, 50 mM KCl, 0.1%
Triton X-100 and 0.4 U DynaZymeTM II DNA
Polymerase, Recombinant (Finnzymes Oy, Espoo,
Finland) in a total volume of 50 μL. Denaturation was
first carried out for 5 minutes at 94°C, followed by
another 35 cycles of denaturation for 30 seconds at
94°C, primer annealing for 50 seconds at 57°C, and
primer extension for 50 seconds at 72°C. Finally,
extension was performed for 5 minutes at 72°C, and
then at 4°C for 30 minutes. HinfI restriction enzyme
(New England Biolabs Inc, Ipswich, MA, USA) analysis
and subsequent electrophoresis in a 2.5% MetaPhor®
agarose gel (Cambrex Corp, East Rutherford, NJ,
USA) revealed the mutational status of the subject.
Each time PCR was performed to detect MTHFR
C677T polymorphism, known positive and negative
controls were used in order to obtain accurate results.
We used MTHFR-TT to represent the homologous
polymorphism, MTHFR-CT to represent the
heterologous polymorphism, and MTHFR-all to
represent any 1 of the polymorphisms.
Plasma Hcy level was measured using an enzyme
immunoassay (Axis® Homocysteine EIA, Axis
Biochemicals ASA, Oslo, Norway), according to the
manufacturer’s instructions. The range for
measurement was 2.0–50.0 μmol/L.
Serum vitamin B12 and folate levels were measured
with a radioimmunoassay (Radioassay Kit Vitamin
B12 [57Co]/Folate [126I], ICN Pharmaceuticals Inc,
Costa Mesa, CA, USA). Vitamin B6 was measured
with a radioenzymatic assay (RK-VB6, Buhlmann
Laboratories AG, Allschwil, Switzerland). Procedures
were performed according to the manufacturers’
instructions.
Complete blood count was measured with an
automated hematology analyzer (Sysmex SE9000,
Toa Medical Electronics Co Ltd, Kobe, Japan). Total
cholesterol, triglycerides and FBS were determined
with the SMAC-II Analyzer (Technicon Corp,
Tarrytown, NY, USA).
ANOVA and the Chi-squared test were used to
check the statistical significance of trends among
parameters. The Scheffe test was used for multiple
comparison if ANOVA results were significant.
Multivariate linear regression was used to detect the
effect of logHcy levels after adjusting for other
variables. As plasma Hcy levels were known to be not
normally distributed, we used the Kolmogorov-
Smirnov method to test whether logHcy or the
square root of Hcy was better at representing Hcy.
The results showed that logHcy represented Hcy
levels best, although Hcy, logHcy and the square
root of Hcy were not normally distributed. Thus, we
used logHcy instead of Hcy.
Results
Of the 106 subjects, 42 were in Group A (healthy), 20
in Group B (type 2 DM), 11 in Group C (DVT), and
33 in Group D (CAD). The mean ages in groups A, B,
C, and D were 64.9 ± 5.4 years (range, 60–78 years),
64.3 ± 15.0 years (range, 35–86 years), 63.5 ± 13.9
years (range, 40–83 years), and 69.3 ± 11.4 years
(range, 33–85 years), respectively.
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Differences in the various parameters
Table 1 shows the various parameters in the 4 groups.
FBS, Hcy and gender were significantly different
among the 4 groups, based on ANOVA (p < 0.001,
p < 0.001, p = 0.016, respectively). Plasma Hcy was
lowest in the healthy subjects, higher in diabetics,
followed by patients with DVT, and highest in patients
with CAD. Differences were significant between healthy
subjects and CAD patients, and between DM and
CAD patients, based on the Scheffe test (p < 0.001,
p = 0.002, respectively) (Table 2). There was a greater
proportion of males in Group D (CAD) than in Group
A (healthy) (p = 0.016). On the other hand, there was
no significant difference among the groups regarding
MTHFR 677TT and MTHFR 677CT polymorphism
(p = 0.580, p = 0.964, respectively).
Influence of the various parameters and MTHFR
mutations on plasma Hcy
Multivariate analysis showed that MTHFR-all could
affect plasma logHcy levels in all 4 groups (p < 0.005,
Table 3), MTHFR-TT polymorphism and triglycerides
could affect plasma logHcy level in the CAD patients
(p = 0.005, p = 0.006, respectively). Putting all groups
together, we found that triglycerides and vitamin B12
could affect logHcy level (p < 0.005, p = 0.026,
respectively).
Table 2. Scheffe test for the 3 significant parameters from
Table 1
p
Fasting blood sugar
Healthy vs DM < 0.001
Healthy vs DVT 0.833
Healthy vs CAD 0.945
DM vs DVT 0.044
DM vs CAD < 0.001
DVT vs CAD 0.969
Homocysteine
Healthy vs DM 0.999
Healthy vs DVT 0.341
Healthy vs CAD < 0.001
DM vs DVT 0.492
DM vs CAD 0.002
DVT vs CAD 0.507
Gender
Healthy vs DM 0.588
Healthy vs DVT 1.0
Healthy vs CAD 0.016
DM vs DVT 1.0
DM vs CAD 0.209
DVT vs CAD 0.139
CAD = coronary artery disease; DM = diabetes mellitus; DVT = deep
vein thrombosis.
Table 1. Mean of various parameters and their differences
Group A (Healthy) Group B (DM) Group C (DVT) Group D (CAD) Total
p
n = 42 n = 20 n = 11 n = 33 (N = 106)
Age (yr) 64.9 ± 5.4 64.3 ± 15.0 63.5 ± 13.9 69.3 ± 11.4 66.0 ± 10.7 0.201*
Platelet (× 109/μL) 271 ± 354 188 ± 121 214 ± 53 238 ± 240 239 ± 265 0.699*
Cholesterol (mg/dL) 178 ± 50 173 ± 64 183 ± 39 187 ± 40 180 ± 49 0.778*
Triglycerides (mg/dL) 121 ± 76 132 ± 55 127 ± 44 168 ± 113 139 ± 86 0.107*
FBS (mg/dL) 101.7 ± 26.0 173.1 ± 90.3 117.8 ± 34.8 109.0 ± 46.7 119.1 ± 56.8 < 0.001*
Hcy (μmol/L) 9.0 ± 7.7 9.4 ± 7.0 14.8 ± 9.6 19.8 ± 11.9 13.0 ± 10.3 < 0.001*
Folate (μg/L) 9.1 ± 3.9 9.4 ± 5.9 8.1 ± 3.1 9.4 ± 5.5 9.2 ± 4.7 0.874*
B6 (nmol/L) 59.3 ± 42.2 53.0 ± 55.4 34.2 ± 26.9 70.3 ± 54.1 58.9 ± 48.6 0.175*
B12 (ng/L) 581 ± 354 609 ± 346 581 ± 425 463 ± 482 546 ± 406 0.548*
Gender (M/F) 21/21 12/8 6/5 26/7 65/41 0.016†
MTHFR-TT‡ (%) 7.3 10.0 27.3 9.1 10.5 0.580†
MTHFR-CT‡ (%) 26.8 25.0 18.2 27.3 25.7 0.964†
History of smoking (%) 26.2 35.0 36.4 39.4 33.0 0.232†
History of alcohol consumption (%) 21.4 30.0 18.2 21.2 22.6 0.867†
*ANOVA; †r2 (linear-by-linear association); ‡MTHFR-TT = homologous polymorphism and MTHFR-CT = heterologous polymorphism. CAD = coronary
artery disease; DM = diabetes mellitus; DVT = deep vein thrombosis; FBS = fasting blood sugar; Hcy = homocysteine; MTHFR =
methylenetetrahydrofolate reductase gene.
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Multivariate analysis, using the stepwise method,
showed that triglycerides had the highest degree of
influence on logHcy in the healthy. The most influen-
tial factors were cholesterol in the diabetics and
triglycerides and MTHFR-TT polymorphism in the
CAD group. Putting all groups together, the weight
of effect was in order of triglycerides, MTHFR-TT and
vitamin B12 (Table 4).
Discussion
Thromboembolic disease occurs less frequently in
Chinese than in Caucasians.1–3 During the past few
years, much effort has been made to better understand
the causes of idiopathic venous thrombosis, i.e. the
discovery of factor V Leiden, PT20210A allele and
MTHFR gene polymorphism.7–14 Although factor V
Leiden and PT20210A allele have been found to be
the most frequent causes of thromboembolic disease
in the West, they are absent in the Chinese.4–6,15
However, MTHFR C677T polymorphism can be
found in Chinese subjects.6 MTHFR polymorphism
itself is not a risk factor of thromboembolic disease,
but high plasma levels of the amino acid Hcy are.16
One of the main functions of MTHFR is remethyla-
tion of Hcy into methionine.17 A common MTHFR
polymorphism, an alanine-to-valine substitution,
renders the enzyme thermolabile, elevating plasma
levels of Hcy,18 which increases the risk of occlusive
vascular disease.19 However, in addition to genetic
factors, plasma Hcy levels can also be influenced by
environmental factors such as folate, and vitamins B6
and B12.20–22 Although the sample size in the present
study was not large, this is 1 of the few studies on
Chinese subjects. The influence of genetic and
environmental factors on Hcy levels was compared in
4 groups representing different degrees of risk for
thromboembolic disease in Chinese.
We found that plasma Hcy was lowest in the
healthy subjects, higher in diabetics, followed by
patients with DVT, and highest in patients with CAD
(Table 1). The Scheffe test showed significantly higher
plasma Hcy in CAD patients than in DM patients and
healthy subjects (Table 2). However, there was no
significant difference in the percentage of MTHFR
C677T polymorphism, either -CT or -TT, among the
4 groups. This demonstrated that MTHFR poly-
Table 3. Influence of different variables on logHcy* levels (p, multivariate analysis)
MTHFR-all† MTHFR-TT† MTHFR-CT† TC TG PLT B12 B6 Folate Age Gender
Group
A (Healthy) < 0.005 0.33 0.046 0.56 0.84 0.36 0.26 0.45 1.00 0.38 0.33
B (DM) < 0.005 0.89 0.62 0.35 0.36 0.86 0.38 0.86 0.92 0.22 0.72
C (DVT) < 0.005 – – – – – – – – – –
D (CAD) < 0.005 0.005 0.48 0.06 0.006 0.05 0.84 0.12 0.11 0.14 0.12
A+B+C+D < 0.005 0.34 0.03 0.06 < 0.005 0.83 0.026 0.21 0.64 0.06 0.21
*LogHcy = dependent variable; †MTHFR-TT = homologous polymorphism, MTHFR-CT = heterologous polymorphism, and MTHFR-all = MTHFR-TT
+ MTHFR-CT. CAD = coronary artery disease; DM = diabetes mellitus; DVT = deep vein thrombosis; Hcy = homocysteine; MTHFR =
methylenetetrahydrofolate reductase gene; PLT = platelets; TC = total cholesterol; TG = triglycerides.
Table 4. Degree of influence of different variables on logHcy levels (stepwise method)
Model 1 Model 2 Model 3
Group
A (Healthy) Triglycerides Vitamin B6 –
B (DM) Cholesterol – –
C (DVT) Gender MTHFR-all* –
D (CAD) Triglycerides MTHFR-TT* –
A+B+C+D Triglycerides MTHFR-TT* Vitamin B12
The order of influence = Model 1 > Model 2 > Model 3.
*MTHFR-all = homologous + heterologous polymorphism and MTHFR-TT = homologous polymorphism. CAD = coronary artery disease; DM = diabetes
mellitus; DVT = deep vein thrombosis; Hcy = homocysteine; MTHFR = methylenetetrahydrofolate reductase gene.
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morphism itself was not a risk factor for throm-
boembolic disease, but plasma Hcy level was. The
cause of this discrepancy in the influence of MTHFR
polymorphism and plasma Hcy in our study is not
known; perhaps the small sample size or other unknown
factors played a role. Further studies with a larger
sample size should be performed to obtain clearer
conclusions.
Although there was no significant difference in the
percentages of MTHFR polymorphism among the 4
groups, on multivariate analysis, we found that MTHFR
polymorphism affected the logHcy level in all 4 groups
(Table 3). MTHFR 677TT polymorphism affected
the logHcy level in CAD patients, and MTHFR 677CT
polymorphism affected Group A (healthy) and all
groups combined (A+B+C+D). Thus, MTHFR seemed
to be able to affect plasma Hcy levels in the different
groups of subjects in our study. Vitamin B12 affected
plasma Hcy in all groups of subjects, and triglycerides
affected logHcy in CAD patients and all groups
combined (p = 0.006 and p < 0.0005, respectively).
This demonstrated that plasma Hcy levels were affected
by multiple factors.
Males usually have higher plasma Hcy;23 male
gender is a well-known risk factor for CAD, and this
was also shown in our study (Table 2). On the other
hand, since the status of male gender did not affect
DVT, there must be multiple influences leading to
DVT, and plasma Hcy probably plays a less important
role in the cause of DVT.
From the present preliminary study, we conclude
that plasma Hcy level is a risk factor for CAD. Many
factors including MTHFR polymorphism, vitamin
B12, triglycerides, gender and total cholesterol
might affect Hcy levels in different diseases and
conditions.
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